Escitalopram in the Treatment of Dysthymic Disorder, Double Blind
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This is a 12-week double-blind placebo-controlled study of Escitalopram in treatment of
dysthymic Disorder (low-grade chronic depression), with a 12 week open-label extension phase.
It is hypothesized that Escitalopram will be superior to placebo in improving depression, as
well as psychosocial, temperamental, and cognitive functioning.